According to the World Health Organisation (WHO), Cardiometabolic diseases (CMDs) are the number-one cause of death in the world.
ADHD is one of the most common neurodevelopmental disorders not only of childhood, as is often assumed by the public, but also one that can last into adulthood, affecting between 3% and 5% of adults worldwide.
In recent years, there has been increasing concern that adults with ADHD are at greater risk for developing adverse cardiovascular events, but screening, diagnosis, and treatment guidelines for ADHD patients with co-occurring cardiometabolic disease do not exist, as knowledge around ADHD still is far from complete. However, it is known that comorbidities, including cardiometabolic diseases, are common in ADHD and are estimated as the main cost drivers.1
Therefore, TIMESPAN aims to improve not only the assessment of the risks involved for patients, but also to review and improve already existing treatments for patients with ADHD who also have cardiometabolic disease.
Hodgkins P et al. (2011). Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis. Prim Care Companion CNS Disord, 13(2): PCC.10m01030
Libutzki B et al. (2019). Direct medical costs of ADHD and its comorbid conditions on basis of a claims data analysis. European Psychiatr: the journal of the Association of European Psychiatrists, 58: pp. 38-44
Du Rietz E et al. (2020). Trajectories of healthcare utilization and costs of psychiatric and somatic multimorbidity in adults with childhood ADHD: a prospective register-based study. J Child Psychol Psychiatry, 61(9): pp. 959-968